Premium
Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug development
Author(s) -
Pang David C.
Publication year - 1988
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430120203
Subject(s) - phosphodiesterase , cyclic nucleotide phosphodiesterase , nucleotide , cyclic nucleotide , pde10a , isozyme , nucleoside , intracellular , biochemistry , chemistry , enzyme , phosphodiesterase 3 , biology , gene
Cyclic nucleotide phosphodiesterases catalyze the hydrolysis of 3′,5′ cyclic nucleotides to the corresponding nucleoside 5′ monophosphates. Multiple forms of cyclic nucleotide phosphodiesterase have been identified in both the cardiac muscle and vascular smooth muscle from various species. These isozymes differ in apparent molecular mass, chromatographic properties, substrate specificity, immunologic reactivity, sensitivity to inhibitors, and mode of regulation. The phosphodiesterases play important roles in the regulation of cyclic nucleotide concentrations, which in turn mediate cellular responses to a variety of biological stimuli. The development of phosphodiesterase inhibitors to increase intracellular cyclic nucleotide levels represents an important pharmacological approach to the treatment of various cardiovascular diseases.